Cardiac Dysfunction in Medulloblastoma Survivors Treated with Photon Irradiation

Chantel Cacciotti (✉ Chantel.Cacciotti@lhsc.on.ca)

Children's Hospital of Western Ontario

Christine Chordas

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Katie Valentino

Ann & Robert H. Lurie Children's Hospital

Rudy Allen

Ann & Robert H. Lurie Children's Hospital

Alicia Lenzen

Ann & Robert H. Lurie Children's Hospital

Karen Burns

Cincinnati Children's Hospital Medical Center

Rajaram Nagarajan

Cincinnati Children's Hospital Medical Center

Peter Manley

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Natasha Pillay-Smiley

Cincinnati Children's Hospital Medical Center

Research Article

Keywords: pediatric, brain tumor, cardiac toxicity, radiation, ECHO surveillance, echocardiogram, ejection fraction, shortening fraction

Posted Date: February 24th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1373883/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Introduction. Medulloblastoma is an aggressive central nervous system (CNS) tumor that occurs mostly in the pediatric population. Treatment often includes a combination of surgical resection, craniospinal irradiation (CSI) and chemotherapy. Children who receive standard photon CSI are at risk for cardiac toxicities including coronary artery disease, left ventricular scarring and dysfunction, valvular damage, and atherosclerosis. Current survivorship guidelines recommend routine echocardiogram (ECHO) surveillance. In this multi-institution study, we describe markers of cardiac dysfunction in medulloblastoma survivors.

Methods. A retrospective chart review of medulloblastoma patients who had photon beam CSI followed by ECHO between 1980 and 2010 at Lurie Children's Hospital and Dana-Farber/Boston Children's Hospital.

Results. During the 30-year study period, 168 medulloblastoma patient records were identified. Included in this study were the 75 patients who received CSI or spinal radiation and ECHO follow up. The mean age at CSI was 8.6 years (range, 2.9-20), and the mean number of years between radiation (RT) completion and first ECHO was 7.4 (range, 2-16). Mean ejection fraction (EF) was 60.0% and shortening fraction (SF) was 33.8%. Five patients (7%) had abnormal ECHO results: three with EF <50% and two with SF <28%.

Conclusion. Majority of medulloblastoma patients who received CSI have relatively normal ECHOs post treatment, however 7% of patients had abnormal ECHOs. The implication of our study for medulloblastoma survivors is that further investigations are needed in this populations with a more systematic, longitudinal assessment to determine predictors and screenings.

Introduction

Central nervous system (CNS) tumors are the most common solid tumors in children, and the second most common pediatric malignancy after leukemia [1, 2]. Mortality from high-grade CNS tumors is disproportionately greater compared to other childhood malignancies, and even low-grade tumors can be associated with significant morbidity [3–5]. The current therapeutic strategy—typically a combination of surgery, chemotherapy, and radiation (RT)—poses a risk of cardiovascular complications. For example, the Childhood Cancer Cohort study found a 6-fold increased relative risk of myocardial infarction in childhood brain tumor survivors [6]. As survival rates for childhood cancer increase, this population becomes increasingly vulnerable to long-term therapy-related cardiac toxicities. As such, studies focusing on early management of these side effects are critical.

Cardiovascular side effects in pediatric cancer survivors manifest most commonly as pericardial disease—followed by coronary artery disease, cardiomyopathy, left ventricular scarring and dysfunction, valvular abnormalities, and atherosclerosis [6–13]. While the drivers of therapy-induced cardiac toxicities can be multifactorial, the most common causes are radiation therapy with cardiac exposure and chemotherapy. Several studies in pediatric cancer survivor populations point to mediastinal/thoracic radiation (eg, for

Hodgkin's disease and other mediastinal malignancies) as playing a significant role [6, 8, 14]. Cumulative doses of > 30 Gy to the mediastinum/thoracic area are thought to contribute to cardiac damage [14]. Cardiac toxicity in adults who receive RT treatment during childhood is linked to radiation dose, as well as the fraction given and exposed heart volume [6]. It has been known that cumulative doses of > 30 Gy radiation to the mediastinum/thoracic contribute to cardiac damage with further studies suggesting that lower doses (15–35 Gy) may result in damage to the coronary circulation [6, 14]. The risks for different manifestations of cardiac disease are 2- to 6-fold higher when the cardiac RT dose exceeds 15 Gy [7, 13, 14]. Pediatric medulloblastoma patients treated with CSI all receive spinal doses greater than 15 Gy, regardless of treatment protocol, with patients typically receiving 23 to 36 Gy in combination with chemotherapy. Doses to the heart vary, depending on the RT modality; but have been shown to result in doses to the heart that were approximately 50% and 28% of the spinal dose [15, 16]. While the mechanistic underpinning of RT-induced cardiotoxicity is unclear, there is postulation that radiation induced inflammatory reactions, such as the release of tumor necrosis factor, interleukins and transforming growth factor may result in diffuse interstitial fibrosis [16, 17].

In addition to RT, chemotherapy and targeted drug therapies can cause cardiotoxicity in survivors of childhood cancer—particularly anthracyclines, with cumulative lifetime doses of more than 300 mg/m² imparting the highest risk [8, 18], but also alkylating agents and targeted biological agents [10, 19, 20]. Additionally, blood transfusions due to therapy related anemia may contribute to cardiotoxicity by iron overload cardiomyopathy [21–25].

In CNS tumor patients, there is direct cardiac damage from CSI related scatter to the heart. Additionally, cranial RT exposure damages the hypothalamic-pituitary axis [26, 27], which can lead to growth hormone (GH) deficiency, often the first manifestation of hypopituitarism [28, 29]. This can lead to changes in metabolism and/or hormone production that negatively impact obesity, lipid metabolism, insulin resistance, and diabetes mellitus [30–32]—thereby increasing cardiovascular risk.

Although, echocardiogram (ECHO) ejection fraction (EF) and shortening fraction (SF) are the most widely used measures of assessment for left ventricular systolic function, variation exists when alternative means such as cardiovascular magnetic resonance (CMR) or gated single-photon emission computed tomography (SPECT) are used [33].

Precisely because of these risks, a screening electrocardiogram (EKG) upon entry to into long-term follow up, repeated as clinically indicated and serial ECHOs (every 2–5 years) for monitoring left ventricular size and function has been included in the Children's Oncology Group (COG) Survivorship Guidelines since their inception in 2003. These guidelines were developed as a resource for healthcare providers to aid in screening late effects of therapy in asymptomatic survivors of childhood cancers. Risk factors (eg, radiation type and dose tumor location, and exposure to anthracyclines) are taken into consideration when establishing patient-specific follow-up screening plans. In this study, our objective was to retrospectively examine clinical records of pediatric medulloblastoma patients treated with CSI photon radiation and determine the incidence of cardiotoxicity.

Methods

A retrospective cohort study was conducted at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Lurie Children's Hospital. Both the Dana-Farber Cancer Institute and Lurie Children's Hospital IRBs approved this study.

Objectives

Data collected included demographics, details of medulloblastoma diagnosis and therapy, radiation dosing and field, and echocardiogram results.

Inclusion and exclusion criteria

Patients were 1) diagnosed with medulloblastoma between 1980 and 2010, 2) children (< 21 years of age at diagnosis), 3) at least 2 years from end of treatment, 4) received craniospinal or spinal photon beam radiation and had at least one ECHO post-treatment. Patients who received proton beam radiation were excluded.

Statistical analysis

Descriptive methods were used to present demographics, tumor histology and age at diagnosis. Continuous variables were reported as mean, standard deviation, median and ranges. Categorical variables were described by frequency and percentage. Adverse events were evaluated by chi-squared testing, and adverse events over time by generalized estimating equations.

Results

During the study period (1980 to 2010), 168 patients were treated for medulloblastoma, 75 of whom had photon irradiation and ECHO follow up and were therefore included in the study. Of the 75 patients, 73 were treated with CSI at diagnosis, one was treated with CSI at recurrence and one with focal spinal RT. The mean age at CSI was 8.6 years (range, 2.9–20), and the median CSI dose was 23.4 Gy (range, 21.6–39.6) (Table 1). One patient received an additional 9 Gy boost to the spine (C6-S2/3), due to presence of spinal disease. Two patients who initially received RT-sparing treatment, subsequently received spine RT due to recurrent disease, doses at recurrence included 800 cGy focal to T9-10 and 36 Gy CSI. While one patient received only focal spine RT, the remainder (74 out of 75) received CSI: 35% were treated with 36 Gy to the spine and 63% with 21–35 Gy. Patients did not receive anthracyclines as part of their therapy.

Table 1
Characteristics of 75 childhood medulloblastoma survivors

	No. of cases (%)
Gender	
Male	33 (44%)
Female	42 (56%)
Medulloblastoma histological subtype	
Classic	30 (40%)
Desmoplastic or nodular	10 (10%)
Anaplastic or large cell	12 (16%)
Unknown	23 (31%)
Risk Group	
Average	46 (61%)
High	29 (39%)
RT field	
CSI	75 (99%) ^a
Focal RT only	1 (1%) ^b
	Mean (range)
Age at CSI	8.6 (2.9–20)
ECHO	
Age at ECHO	15.6 (0.9–27)
Years post RT at first ECHO	7.4 (2–16)
	Median (range) Gy
CSI dose	23.4 (21.6–39.6)
Total RT dose (CSI + boost)	54 (36-57.6)
^a one patient was treated with RT sparing approach upfront and then with CSI at recurrence	
^b spinal focal RT	

Cardiac dysfunction

Most patients (80%; 60 out of 75) had one ECHO post treatment, and the remainder (20%; 15 out of 75) had repeat cardiac testing. A minority (43%; 32 out of 75) of patients completed therapy prior to the implementation of the COG Survivorship Guidelines, but still had an ECHO performed following completion of therapy. The mean time post-CSI to first ECHO was 7.4 years (range, 2–16), and to second ECHO, when performed, was 11.9 years (range, 8.6–17.3). For the 4% (3/75) who received a third ECHO, the mean time post-RT was 12.6 years (range, 11.4–13.3).

Mean EF in the entire cohort was 60.0% and SF was 33.8%. Five patients (7%) had abnormal ECHO results ($P < .001$): three had EF < 50%, and 2 had SF < 28% (Table 2). All five patients were asymptomatic and treated with observation, with life-style changes suggested for two. Interestingly, four of the five patients with abnormal ECHOs were treated with lower dose irradiation (23.4 Gy CSI), whereas the fifth patient received 36 Gy CSI. Only two of the five patients with abnormal ECHOs had electrocardiograms (ECGs) performed, one of which was normal and the other demonstrated sinus tachycardia with a borderline prolonged QTc. Finally, one of the five patients had a cardiac MRI, which was normal.

Table 2
Summary of cardiac abnormalities in 5 medulloblastoma survivors

Age / gender	Risk diagnosis	Therapies		Years from RT to abnormal ECHO	Abnormalities		Management of cardiac abnormality
		Chemo	CSI dose (Gy) ^a		ECHO (%)	ECG	
13y 2mo/F	AVG	CCG/POG A9961	23.4	7.7	EF 31.6	ND	Repeat ECHO (normal)
8y 6mo/M	AVG	CCG/POG A9961	23.4	7.5	EF 34.9	ND	Repeat ECHO (normal)
6y 7mo/F	AVG	CCG/POG A9961	23.4	5.3	EF 29.6	ND	None
20y 4mo/M	High	POG9631	39	6.5	SF 27.7	Normal	Cardiac MRI (normal), observation
8y 6mo/F	AVG	ACNS0331	23.4	5.7	SF 26.6	Sinus tachycardia; borderline prolonged QTc	Repeat ECHO

^a All 5 patients also received a 54 Gy boost to the primary tumor

Abbreviations: CCG, Children’s Cancer Group; CSI, craniospinal irradiation; ECG, electrocardiogram; ECHO, echocardiogram; ND, not done; POG, Pediatric Oncology Group; UK, unknown

Discussion

With improved survival in patients diagnosed with medulloblastoma over the past four decades, a great deal has been learned about long-term sequelae of treatment and, consequently, more attention has been directed at reducing these treatment-related late effects. By reviewing data from a large volume of patients seen in two pediatric neuro-oncology cancer survivorship programs, we show that 7% had abnormal ECHO findings, specifically abnormalities in EF or SF. Brain tumor survivors are at high risk for stroke, dyslipidemia and obesity and it is uncertain if these factors have a more profound long-term impact on their cardiac health as they age in comparison to the direct toxicity from radiation and chemotherapy. Further long-term cardiac investigations are needed in this population given that a small cohort of our patients had abnormal ECHO findings.

Although echocardiographic EF and SF have traditionally been used to monitor left ventricular systolic function, EF and SF may not reflect ventricular contractility and instead are influenced by ventricular overload and afterload [8]. They are operator dependent and have demonstrated poor reproducibility in a large multi-centered study of healthy pediatric patients [34]. Thus, it has been postulated that perhaps EF and SF are not the best measure to evaluate cardiac function post treatment and we worry that cardiac disease may have been underrepresented in our patient cohort.

Alternatively, evaluation of myocardial strain by ECHO may be considered. Myocardial strain is a non-invasive measurement on 2-dimensional speckle tracing ECHO, it is reported as a percent that can be measured by global longitudinal strain (GLS), global circumferential strain (GCS) and global radial strain (GRS). Prior studies have demonstrated decreased GLS and GSC despite normal left ventricular EF or SF in childhood cancer survivors, implying presence of LV systolic dysfunction or subclinical myocardial dysfunction [35–39]. Reduction in GLS by 10 to 15% appears to be the most useful parameter for prediction of cardiotoxicity, as it may define a decrease in LVEF or heart failure. Thus, measures of cardiac strain in late survivors of childhood cancer may be abnormal, even in the context of normal LVEF. The true value in predicting subsequent ventricular dysfunction or heart failure needs to be further evaluated. In a recent article by Martinez et al, the ECHO results from 51 patients treated for pediatric CNS malignancies at Cincinnati Children's Hospital with CSI who had at least one ECHO done after CSI, did not have abnormal left ventricular dysfunction noted [39]. However, abnormal cardiac strain was demonstrated [39].

Proton beam RT in brain tumor patients receiving CSI may be advantageous given the lack of “scatter” that is associated with traditional photon beam RT. As such, protons may eliminate the cardiac RT exposure in patients receiving CSI. Several groups have demonstrated the advantage of proton RT in sparing critical normal structures [40–46]. No late cardiac effects were reported by Yock et al [44] in 59 pediatric medulloblastoma patients treated with proton RT with a median seven year follow up, although no ECGs or ECHOs were performed in their study; therefore, only symptomatic cardiac disease would have been detected. Although, proton irradiation “spares” the heart, the hypothalamic-pituitary axis remains affected, which in turn may increase the risk of cardiovascular disease in these survivors [16].

Thus, further studies are needed to determine the presence or absence of asymptomatic cardiac dysfunction in this population.

In our study, variation exists in the management and screening of pediatric cancer survivor patients after completion of therapy [12, 40]. It is important to continue to screen for cardiac dysfunction as the pediatric CNS survivorship population reaches older adulthood and acquires more medical morbidity (eg, dyslipidemia and stroke).

While additional studies need to be done to further investigate if cardiac strain should be followed as part of survivorship guidelines in pediatric survivors of CNS tumors, the data by Martinez et al is compelling and should be considered for evaluation of these patients. While additional research is underway, one suggested approach would be to use a multipronged approach to assess for cardiac dysfunction in pediatric CNS survivors based on individual risk, with greater focus on early identification and management of comorbidities such as decreased exercise tolerance, dyslipidemia, and management of endocrinopathies. In patients that have received CSI, a screening ECG and ECHO should continue to be performed in all patients. In addition to radiation, an assessment of a patient's individual cardiac risk factors such as ethnicity, obesity, dyslipidemia, inability to perform aerobic exercise due to physical deconditioning or tumor/treatment induced or iron overload should always be factored into any treatment plan.

Our study has limitations. A limited number of repeat echocardiograms were performed, which limited our ability to capture changes over time. In addition, radiation doses were limited to spinal or CSI dosing; estimated doses to the cardiac muscle were not available. Furthermore, while our study charts range from 1980 to 2010, the first version of the COG guidelines was only published in 2003, and this is the first time radiation was formally included in cardiotoxicity monitoring recommendations. All patients in our cohort who had ECHOs performed were done following the publication of these recommendations. Prior to this, Steinherz and colleagues published the first imaging recommendations for cardiac monitoring in children in 1992, but this was limited to patients who had received anthracyclines [41]. This may account for the lack of screening in some of the patients in this study, as medulloblastoma patients are not treated with anthracyclines. Although the mean duration from treatment to ECHO monitoring was 7.4 years, most patients underwent only one ECHO evaluation and this could lead to underestimations of long-term cardiac-associated side effects. A large percentage of patients did not have ECHOs completed and were excluded from the study and information is not available. Given that the incidence of cardiac disease increases with age and longer duration from treatment, this relatively young cohort may underestimate the risk of cardiac dysfunction in medulloblastoma survivors. Additional longitudinal studies would be beneficial. Further studies should also evaluate whether access to care, consistent follow up, formal survivorship screening programs or lack of insurance coverage serve as barriers to obtaining imaging. Cardiac health in CNS survivors is multifactorial, as such the weight of each factor is unknown and further studies evaluating other confounding factors such as GH deficiency may be beneficial.

Conclusion

Risk for cardiac morbidity and mortality is multifactorial in childhood CNS tumors survivors, resulting from treatment modalities and their sequelae. Such individuals require ongoing monitoring for these late effects, especially as they approach ages in which cardiovascular and cerebrovascular disease is more prevalent. The risk and extent of cardiac toxicity following CSI is not well documented in the literature, although existent. Long-term, ongoing follow up in CNS survivors is critical to evaluate risk of therapy, including late onset cardiac toxicity. Proton radiation has the potential to deliver spinal radiation while eliminating cardiac dosing and ongoing research will demonstrate if this will help mitigate long term risk. Further long term follow up studies specific to pediatric CNS survivors are needed to better determine cardiac late effects in this population and the frequency and modality of cardiac monitoring, as patients with cardiac abnormalities may be asymptomatic and our current surveillance strategy may not be effective as our patients' transition to adulthood.

Declarations

Acknowledgment: The authors have no further acknowledgments

Funding: The authors declare that no funds, grants, or other support were received during the preparation of this manuscript

Competing Interests: The authors have no relevant financial or non-financial interests to disclose.

Author Contributions: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Dr. Chantel Cacciotti, Christine Chordas, Katie Valentino, Dr. Peter Manley and Dr. Natasha Pillay-Smile. The first draft of the manuscript was written by Dr. Chantel Cacciotti and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Data Availability: *The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request*

Ethic Approval: *This study was performed in line with the principles of the local research ethics committee at the corresponding institutions.* Both the Dana-Farber Cancer Institute and Lurie Children's Hospital IRBs approved this study.

References

1. Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS (1999) Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst 91: 1051-1058 doi:10.1093/jnci/91.12.1051
2. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1975-2016), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission.

3. Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, Hudson MM, Donaldson SS, King AA, Stovall M, Krull KR, Robison LL, Packer RJ (2009) Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. *J Natl Cancer Inst* 101: 946-958 doi:10.1093/jnci/djp148
4. Robinson KE, Fraley CE, Pearson MM, Kuttesch JF, Compas BE (2013) Neurocognitive late effects of pediatric brain tumors of the posterior fossa: a quantitative review. *J Int Neuropsychol Soc* 19: 44-53 doi:10.1017/S1355617712000987
5. Turner CD, Rey-Casserly C, Liptak CC, Chordas C (2009) Late effects of therapy for pediatric brain tumor survivors. *J Child Neurol* 24: 1455-1463 doi:10.1177/0883073809341709
6. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, Donaldson SS, Green DM, Sklar CA, Robison LL, Leisenring WM (2009) Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. *BMJ* 339: b4606 doi:10.1136/bmj.b4606
7. Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, Stovall M, Chow EJ, Sklar CA, Mulrooney DA, Mertens AC, Border W, Durand JB, Robison LL, Meacham LR (2013) Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. *J Clin Oncol* 31: 3673-3680 doi:10.1200/JCO.2013.49.3205
8. Bansal N, Amdani S, Lipshultz ER, Lipshultz SE (2017) Chemotherapy-induced cardiotoxicity in children. *Expert Opin Drug Metab Toxicol* 13: 817-832 doi:10.1080/17425255.2017.1351547
9. Ewer MS, Ewer SM (2015) Cardiotoxicity of anticancer treatments. *Nat Rev Cardiol* 12: 547-558 doi:10.1038/nrcardio.2015.65
10. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC (2005) Cardiotoxicity of cancer therapy. *J Clin Oncol* 23: 7685-7696 doi:10.1200/JCO.2005.08.789
11. Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, Robison LL, Yasui Y (2008) Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. *J Natl Cancer Inst* 100: 1368-1379 doi:10.1093/jnci/djn310
12. Ryan TD, Border WL, Baker-Smith C, Barac A, Bock MJ, Canobbio MM, Choueiter NF, Chowdhury D, Gambetta KE, Glickstein JS, Kondapalli L, Mital S, Peiris V, Schiff RJ, Spicer RL, Towbin JA, Chen MH (2019) The landscape of cardiovascular care in pediatric cancer patients and survivors: a survey by the ACC Pediatric Cardio-Oncology Work Group. *Cardiooncology* 5: 16 doi:10.1186/s40959-019-0051-8
13. van der Pal HJ, van Dalen EC, Hauptmann M, Kok WE, Caron HN, van den Bos C, Oldenburger F, Koning CC, van Leeuwen FE, Kremer LC (2010) Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. *Arch Intern Med* 170: 1247-1255 doi:10.1001/archinternmed.2010.233
14. Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J (2014) Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. *Eur Heart J* 35: 612-623 doi:10.1093/eurheartj/eh114

15. Chojnacka M, Skowrońska-Gardas A, Morawska-Kaczyńska M, Zygmuntowicz-Piętka A, Pędziwiatr K, Semaniak A (2010) Craniospinal radiotherapy in children: Electron- or photon-based technique of spinal irradiation. *Rep Pract Oncol Radiother* 15: 21-24 doi:10.1016/j.rpor.2010.01.005
16. Frankart AJ, Nagarajan R, Pater L (2021) The impact of proton therapy on cardiotoxicity following radiation treatment. *J Thromb Thrombolysis* 51: 877-883 doi:10.1007/s11239-020-02303-4
17. Madan R, Benson R, Sharma DN, Julka PK, Rath GK (2015) Radiation induced heart disease: Pathogenesis, management and review literature. *J Egypt Natl Canc Inst* 27: 187-193 doi:10.1016/j.jnci.2015.07.005
18. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. *N Engl J Med* 324: 808-815 doi:10.1056/NEJM199103213241205
19. Rao VU, Reeves DJ, Chugh AR, O'Quinn R, Fradley MG, Raghavendra M, Dent S, Barac A, Lenihan D (2021) Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review. *J Am Coll Cardiol* 77: 2693-2716 doi:10.1016/j.jacc.2021.04.009
20. Babiker HM, McBride A, Newton M, Boehmer LM, Drucker AG, Gowan M, Cassagnol M, Camenisch TD, Anwer F, Hollands JM (2018) Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. *Crit Rev Oncol Hematol* 126: 186-200 doi:10.1016/j.critrevonc.2018.03.014
21. de Ville de Goyet M, Moniotte S, Robert A, Dupont S, Vermeylen C, Veyckemans F, Brichard B (2013) Iron overload in children undergoing cancer treatments. *Pediatr Blood Cancer* 60: 1982-1987 doi:10.1002/pbc.24705
22. Emy PY, Levin TL, Sheth SS, Ruzal-Shapiro C, Garvin J, Berdon WE (1997) Iron overload in reticuloendothelial systems of pediatric oncology patients who have undergone transfusions: MR observations. *AJR Am J Roentgenol* 168: 1011-1015 doi:10.2214/ajr.168.4.9124106
23. Ruccione KS, Wood JC, Sposto R, Malvar J, Chen C, Freyer DR (2014) Characterization of transfusion-derived iron deposition in childhood cancer survivors. *Cancer Epidemiol Biomarkers Prev* 23: 1913-1919 doi:10.1158/1055-9965.EPI-14-0292
24. Schempp A, Lee J, Kearney S, Mulrooney DA, Smith AR (2016) Iron Overload in Survivors of Childhood Cancer. *J Pediatr Hematol Oncol* 38: 27-31 doi:10.1097/MPH.0000000000000444
25. Sait S, Zaghloul N, Patel A, Shah T, Iacobas I, Calderwood S (2014) Transfusion related iron overload in pediatric oncology patients treated at a tertiary care centre and treatment with chelation therapy. *Pediatr Blood Cancer* 61: 2319-2320 doi:10.1002/pbc.25189
26. Darzy KH, Shalet SM (2009) Hypopituitarism following Radiotherapy Revisited. *Endocr Dev* 15: 1-24 doi:10.1159/000207607
27. Merchant TE, Rose SR, Bosley C, Wu S, Xiong X, Lustig RH (2011) Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. *J Clin Oncol* 29: 4776-4780 doi:10.1200/JCO.2011.37.9453

28. Rutter MM, Rose SR (2007) Long-term endocrine sequelae of childhood cancer. *Curr Opin Pediatr* 19: 480-487 doi:10.1097/MOP.0b013e3282058b56
29. Mulder RL, Kremer LC, van Santen HM, Ket JL, van Trotsenburg AS, Koning CC, Schouten-van Meeteren AY, Caron HN, Neggers SJ, van Dalen EC (2009) Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review. *Cancer Treat Rev* 35: 616-632 doi:10.1016/j.ctrv.2009.06.004
30. Cooksey R, Wu SY, Klesse L, Oden JD, Bland RE, Hodges JC, Gargan L, Vega GL, Bowers DC (2019) Metabolic syndrome is a sequela of radiation exposure in hypothalamic obesity among survivors of childhood brain tumors. *J Investig Med* 67: 295-302 doi:10.1136/jim-2018-000911
31. Pietilä S, Mäkipernaa A, Sievänen H, Koivisto AM, Wigren T, Lenko HL (2009) Obesity and metabolic changes are common in young childhood brain tumor survivors. *Pediatr Blood Cancer* 52: 853-859 doi:10.1002/pbc.21936
32. Talvensaari KK, Lanning M, Tapanainen P, Knip M (1996) Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. *J Clin Endocrinol Metab* 81: 3051-3055 doi:10.1210/jcem.81.8.8768873
33. Pellikka PA, She L, Holly TA, Lin G, Varadarajan P, Pai RG, Bonow RO, Pohost GM, Panza JA, Berman DS, Prior DL, Asch FM, Borges-Neto S, Grayburn P, Al-Khalidi HR, Miszalski-Jamka K, Desvigne-Nickens P, Lee KL, Velazquez EJ, Oh JK (2018) Variability in Ejection Fraction Measured By Echocardiography, Gated Single-Photon Emission Computed Tomography, and Cardiac Magnetic Resonance in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. *JAMA Netw Open* 1: e181456 doi:10.1001/jamanetworkopen.2018.1456
34. Frommelt PC, Minich LL, Trachtenberg FL, Altmann K, Camarda J, Cohen MS, Colan SD, Dragulescu A, Frommelt MA, Johnson TR, Kovalchin JP, Lin L, Mahgerefteh J, Nutting A, Parra DA, Pearson GD, Pignatelli R, Sachdeva R, Soriano BD, Spurney C, Srivastava S, Statile CJ, Stelter J, Stylianou M, Thankavel PP, Tierney ES, van der Velde ME, Lopez L, Investigators PHN (2019) Challenges With Left Ventricular Functional Parameters: The Pediatric Heart Network Normal Echocardiogram Database. *J Am Soc Echocardiogr* 32: 1331-1338.e1331 doi:10.1016/j.echo.2019.05.025
35. Akam-Venkata J, Kadiu G, Galas J, Lipshultz SE, Aggarwal S (2019) Left ventricle segmental function in childhood cancer survivors using speckle-tracking echocardiography. *Cardiol Young* 29: 1494-1500 doi:10.1017/S1047951119002622
36. Pignatelli RH, Ghazi P, Reddy SC, Thompson P, Cui Q, Castro J, Okcu MF, Jefferies JL (2015) Abnormal Myocardial Strain Indices in Children Receiving Anthracycline Chemotherapy. *Pediatr Cardiol* 36: 1610-1616 doi:10.1007/s00246-015-1203-8
37. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH (2014) Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. *J Am Coll Cardiol* 63: 2751-2768 doi:10.1016/j.jacc.2014.01.073

38. Yu AF, Raikhelkar J, Zabor EC, Tonorezos ES, Moskowitz CS, Adsuar R, Mara E, Huie K, Oeffinger KC, Steingart RM, Liu JE (2016) Two-Dimensional Speckle Tracking Echocardiography Detects Subclinical Left Ventricular Systolic Dysfunction among Adult Survivors of Childhood, Adolescent, and Young Adult Cancer. *Biomed Res Int* 2016: 9363951 doi:10.1155/2016/9363951
39. Martinez HR, Salloum R, Wright E, Bueche L, Khoury PR, Tretter JT, Ryan TD (2021) Echocardiographic myocardial strain analysis describes subclinical cardiac dysfunction after craniospinal irradiation in pediatric and young adult patients with central nervous system tumors. *Cardiooncology* 7: 5 doi:10.1186/s40959-021-00093-z
40. Bhatia N, Lenihan D, Sawyer DB, Lenneman CG (2016) Getting the SCOOP-Survey of Cardiovascular Outcomes From Oncology Patients During Survivorship. *Am J Med Sci* 351: 570-575 doi:10.1016/j.amjms.2016.01.025
41. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, Sandor G, Benson L, Williams R (1992) Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. *Pediatrics* 89: 942-949
42. St Clair WH, Adams JA, Bues M, Fullerton BC, La Shell S, Kooy HM, Loeffler JS, Tarbell NJ (2004) Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. *Int J Radiat Oncol Biol Phys* 58: 727-734 doi:10.1016/S0360-3016(03)01574-8
43. Al-Wassia RK, Ghassal NM, Naga A, Awad NA, Bahadur YA, Constantinescu C (2015) Optimization of Craniospinal Irradiation for Pediatric Medulloblastoma Using VMAT and IMRT. *J Pediatr Hematol Oncol* 37: e405-411 doi:10.1097/MPH.0000000000000418
44. Yock TI, Yeap BY, Ebb DH, Weyman E, Eaton BR, Sherry NA, Jones RM, MacDonald SM, Pulsifer MB, Lavally B, Abrams AN, Huang MS, Marcus KJ, Tarbell NJ (2016) Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. *Lancet Oncol* 17: 287-298 doi:10.1016/S1470-2045(15)00167-9
45. Brown AP, Barney CL, Grosshans DR, McAleer MF, de Groot JF, Puduvalli VK, Tucker SL, Crawford CN, Khan M, Khatua S, Gilbert MR, Brown PD, Mahajan A (2013) Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. *Int J Radiat Oncol Biol Phys* 86: 277-284 doi:10.1016/j.ijrobp.2013.01.014
46. Yuh GE, Loredon LN, Yonemoto LT, Bush DA, Shahnazi K, Preston W, Slater JM, Slater JD (2004) Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. *Cancer J* 10: 386-390 doi:10.1097/00130404-200411000-00009